Excel Diagnostic Imaging Clinics Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2005
NCT00442533
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Excel Diagnostics Imaging Clinics

Active Ingredients

Drugs in Phase 3 Trials (1)

in111-octreoscan (1 trial)

Drugs in Other Trials (1)

fluorothymidine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuroendocrine Tumors (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2